SVA [SINOVAC BIOTECH] 20-F: Indicate the number of outstanding shares of each

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2011-04-22
Original SEC Filing: Click here


Webplus: SVA/20110422/20-F/1/000.htm SEC Original: v219311_20f.htm
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 54,305,961 common shares as of December 31, 2010 o x o x x o o o




Webplus: SVA/20110422/20-F/10_EX-8.1/000.htm SEC Original: v219311_ex8-1.htm
List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company




Webplus: SVA/20110422/20-F/11_EX-12.1/000.htm SEC Original: v219311_ex12-1.htm
Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of




Webplus: SVA/20110422/20-F/12_EX-12.2/000.htm SEC Original: v219311_ex12-2.htm
Certification by the Chief Financial Officer I, Jacob Chik Keung Ho, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in




Webplus: SVA/20110422/20-F/13_EX-13.1/000.htm SEC Original: v219311_ex13-1.htm
Certification by the Chief Executive Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 13 v219311_ex13-1.htm




Webplus: SVA/20110422/20-F/14_EX-13.2/000.htm SEC Original: v219311_ex13-2.htm
Certification by the Chief Financial Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.2 14 v219311_ex13-2.htm




Webplus: SVA/20110422/20-F/15_EX-15.1/000.htm SEC Original: v219311_ex15-1.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S−8 No. 333−161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 22, 2011, with respect to the consolidated financial statements of Sinovac Biotech Ltd., and the effectiveness of internal control over financial reporting



Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 20-F, Date: 2011-04-22CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085

Home Page Forums

By | 2016-03-24T02:02:42+00:00 April 22nd, 2011|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar